Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and
accounts for> 90% of cancers in the kidney. The disease encompasses> 10 histological and …

Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned
from a nonspecific immune approach (in the cytokine era), to targeted therapy against …

Background Patients with renal-cell carcinoma who undergo nephrectomy have no options
for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting …

Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women,
respectively, thus representing the 7th most common cancer in men, and the 10th most …

Background Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was
approved on the basis of a significant improvement in disease-free survival in the KEYNOTE …

Background The first interim analysis of the KEYNOTE-564 study showed improved disease-
free survival with adjuvant pembrolizumab compared with placebo after surgery in patients …

Background The standard of care for locoregional renal cell carcinoma is surgery, but many
patients experience recurrence. The objective of the current study was to determine if …

Background Sunitinib, a vascular endothelial growth factor pathway inhibitor, is an effective
treatment for metastatic renal-cell carcinoma. We sought to determine the efficacy and safety …

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the
clinical management of patients with clear cell and non–clear cell renal carcinoma. These …

All solid tumours require a vascular supply in order to progress. Although the ability to
induce angiogenesis (new blood vessel growth) has long been regarded as essential to this …